1 recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Recruiting 1 |
Follow Tolvaptan Suspension: new trials by email Literature Review of Tolvaptan Suspension trials Research Report on Tolvaptan Suspension
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD) Tolvaptan Suspension, Tolvaptan Tablets - Autosomal Recessive Polycystic Kidney (ARPKD) | Phase 3 | Recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 20 | 2023-01-23 | 2026-10-23 |
Oligohydramnios (1) · Polycystic Kidney Diseases (1) · Polycystic Kidney, Autosomal Recessive (1)
Otsuka Pharmaceutical Development & Commercialization, Inc. (1)
Belgium (1) · Germany (1) · Poland (1) · Spain (1) · United Kingdom (1) · United States (1)